Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000167116 | SCV000217946 | likely benign | Hereditary cancer-predisposing syndrome | 2014-12-10 | criteria provided, single submitter | clinical testing | Co-occurence with a mutation in another gene that clearly explains a proband's phenotype;In silico models in agreement (benign) |
Labcorp Genetics |
RCV000471627 | SCV000542152 | benign | Neurofibromatosis, type 1 | 2024-11-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004558410 | SCV005048665 | likely benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2017-09-12 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Baylor Genetics | RCV004567330 | SCV005052335 | uncertain significance | Juvenile myelomonocytic leukemia | 2023-11-18 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005016506 | SCV005646755 | uncertain significance | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2024-06-11 | criteria provided, single submitter | clinical testing | |
Gharavi Laboratory, |
RCV000782208 | SCV000920689 | uncertain significance | not provided | 2018-09-16 | no assertion criteria provided | research |